Scoop: VA decides against adding Biogen's Aduhelm to its formulary as PBM shuns controversial Alzheimer's drug
The Department of Veterans Affairs has decided to not include Biogen’s pricey new Alzheimer’s drug Aduhelm on its formulary, and its PBM even went so …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
